Integra Lifesciences Holdings Corp

NASDAQ:IART  
42.33
-1.16 (-2.67%)
Products, Other Pre-Announcement

Integra Lifesciences Initiates Immediate Voluntary Global Product Removal Of All Cerelink Intracranial Pressure Monitors

Published: 08/24/2022 11:19 GMT
Integra Lifesciences Holdings Corp (IART) - Integra Lifesciences Holdings Corp - on Aug 18, Initiated Immediate Voluntary Global Product Removal of All Cerelink Intracranial Pressure Monitors.
Integra Lifesciences Holdings Corp- Co Estimates Returns Provision of About 9 Million in Q3 of 2022 and Has Adjusted Its Q3 and FY 2022 Guidance Accordingly.
Integra Lifesciences- Global Removal of Cerelink Intracranial Pressure Monitors Result of Customer Reports That Pressure Readings Were Out of Range.
Integra- Continues Investigation Into Matter to Remedy Observed Issue & Plans to Resume Shipment of Cerelink Monitors After Issues Have Been Resolved.
Integra- Does Not Expect That Voluntary Action Will Have Material Adverse Effect on the Co's Business, Financial Condition Or Results of Operations.
Integra Lifesciences - Global Removal of Cerelink Intracranial Pressure Monitors After Consultation With FDA, Regulatory Authorities Outside of U.S.integra Lifesciences Holdings Corp - Sees Q3 Revenue $374 Million - $382 Million.
Integra Lifesciences Holdings Corp - Sees Q3 Adjusted EPS $0.69 - $0.73.
Integra Lifesciences Holdings Corp - Sees Full Year Revenue $1,548 Million - $1,566 Million.
Integra Lifesciences Holdings Corp - Sees Full Year Adjusted EPS $3.12 - $3.20.